FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

10/23/14 - 20140314767 - Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody....

10/23/14 - - Methods and compositions for treating and diagnosing diseases
Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in...

10/23/14 - 20140314769 - Neutralizing antibodies and methods of use thereof
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins,...

10/23/14 - 20140314770 - Kidney disease targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as...

10/23/14 - 20140314771 - Combination therapy of antibodies against human csf-1r and tlr9 agonist
The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist....

10/23/14 - 20140314772 - Anti-c5a binding moieties with high blocking activity
The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention...

10/23/14 - 20140314773 - Compositions and methods for treating alzheimer's disease
The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino acid sequence GSNK (SEQ ID NO: 1), SNKG(SEQ ID NO: 2), GSNKG (SEQ ID N0:3), CSNKG...

10/23/14 - 20140314774 - Her3 antibodies and uses thereof
Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject....

10/23/14 - 20140314775 - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
Patients having a chronic or acute disease or acute condition, especially patients at the ICU (Intensive Care Unit) suffer from fluid imbalance. The present invention provides a medicament for regulating the fluid balance and/or improving the fluid balance of such patients. Subject matter of the present invention is an anti-Adrenomedullin...

10/23/14 - 20140314776 - Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof....

10/23/14 - 20140314777 - Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
The present invention relates to murine monoclonal antibodies C, F and H which target major neutralizing epitopes of influenza H5 hemagglutinin of clade 2.3 and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using murine monoclonal antibodies C,...

10/16/14 - 20140308288 - Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been...

10/16/14 - 20140308289 - Extracellular histones as biomarkers for prognosis and molecular targets for therapy
Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as...

10/16/14 - 20140308290 - Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody....

10/16/14 - 20140308291 - Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections....

10/09/14 - - Novel antibodies and uses thereof
The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof....

10/09/14 - 20140302041 - Anti-axl antibodies and uses thereof
The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region...

10/09/14 - 20140302042 - Methods of predicting prognosis in cancer
A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed....

10/09/14 - 20140302043 - Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection....

10/09/14 - 20140302044 - Mcpip protection against osteoclast production
Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms....

10/09/14 - 20140302045 - Igy composition for use in celiac disease
The present invention relates to an IgY composition characterized in that said IgY composition contains IgY antibodies, fragments, and/or Fab fragments thereof that specifically bind to a peptide with the amino acid sequence of SEQ ID NO: 1 and to the use of this IgY composition in the therapy of...

10/09/14 - 20140302046 - Immunological targeting of pathological tau proteins
The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed...

10/09/14 - 20140302047 - Thrombin-binding antibody molecules and uses thereof
This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin....

10/09/14 - 20140302048 - Plasma kallikrein binding proteins
Plasma kallikrein binding proteins and methods of using such proteins are described....

10/09/14 - 20140302049 - Anti-gpr49 antibodies
Described herein are to antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies....

10/09/14 - 20140302050 - Targeting an amphiregulin-derived cell surface neo-epitope
Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies....

10/02/14 - 20140294842 - Assays, methods and means
A novel class of hydroxylases is described having the amino acid sequence of SEQ ID No. 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF...

10/02/14 - 20140294843 - Diagnosis and treatment of copd
Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of...

10/02/14 - 20140294844 - Prion protein antibodies for the treatment of alzheimer's disease
The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues...

10/02/14 - 20140294845 - Anti-pleiotrophin antibodies and methods of use thereof
The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an...

10/02/14 - 20140294846 - Function and regulation of adamts-1
The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1....

10/02/14 - 20140294847 - Biological materials related to c-met
The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to...

10/02/14 - 20140294848 - Novel targets for regulation of angiogenesis
The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related...

10/02/14 - 20140294849 - Compositions and uses
The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before...

09/25/14 - 20140286952 - Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized...

09/25/14 - 20140286953 - Hepcidin, hepcidin antagonists and methods of use
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders....

09/25/14 - 20140286954 - Tau protease compositions and methods of use
Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and...

09/25/14 - 20140286955 - Notch agonists for the treatment of cancer
The present invention is directed to methods of treating and preventing acute myeloid leukemia and acute myeloid leukemia relapse disease in a subject that involve administering a Notch receptor agonist....

09/25/14 - 20140286956 - Modulating inflammasome activity and inflammation in the central nervous system
Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and...

09/25/14 - 20140286957 - Antibodies to cd1d
Isolated antibodies or antigen binding portions thereof that bind to CD1d. These antibodies and antigen binding portions thereof have application in treatment of conditions involving NKT cell effector function....

09/25/14 - 20140286958 - Interleukin-31 monoclonal antibody
An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats....

09/18/14 - 20140271650 - Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin...

09/18/14 - 20140271651 - Anti-gp73 monoclonal antibodies and methods of obtaining the same
Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample....

09/18/14 - 20140271652 - Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting...

09/18/14 - 20140271653 - Human antibodies to respiratory syncytial virus f protein and methods of use thereof
The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby...

09/18/14 - 20140271654 - Methods for treating bone gap defects
The invention provides a method of enhancing bone gap defect healing involving administering a sclerostin inhibitor....

09/18/14 - 20140271655 - Neutralizing anti-influenza a virus antibodies and uses thereof
The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode,...

09/18/14 - 20140271656 - Optimized antigens of pneumocystis and use thereof
Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the...

09/18/14 - 20140271657 - Combinatorial compositions and methods of treating hemoglobinopathies
Provided herein are compositions and methods for increasing fetal hemoglobin expression (HbF) for the treatment and/or amelioration of the symptoms of a hemoglobinpathy in a mammal. The compositions comprise a combination of one or more inhibitors of BCL11A expression or activity with epigenetic modifiers, such as inhibitors of DNA methylation...

09/11/14 - - Specific binding proteins and uses thereof
The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of...

09/11/14 - 20140255411 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung...

09/11/14 - 20140255412 - Pharmaceutical composition of an antigenic tau peptide reconstituted in a liposome and related antibodies and cell lines
The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical compositions comprising an antigenic peptide, particularly an antigenic phopho-peptide mimicking a...

09/11/14 - 20140255413 - Combination therapy for neoplasia treatment
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the...

09/11/14 - 20140255414 - Diagnostic antibody assay
Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided....

09/11/14 - 20140255415 - Lingo binding molecules and pharmaceutical use thereof
The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which...

09/11/14 - 20140255416 - Peptides derived from camplobacter jejuni and their use in vaccination
Disclosed are polypeptides for Campylobacter jejuni that are useful as immungenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins....

09/11/14 - 20140255417 - Modulation of macrophage activation
The invention is generally directed to promoting M1-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the...